Drug Interaction Report
1 drug interaction and 7 additional warnings found for the following 2 drugs:
- granisetron
- trofinetide
Drug interactions
Moderate drug interactions
Moderate:granisetron trofinetide
Applies to: granisetron, trofinetide
Trofinetide may increase the blood levels and effects of granisetron.
Talk to your doctor if you have any questions or concerns.
You may need more frequent monitoring to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects.
It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Disease interactions
7 potential interactionsApplies to: 7 conditions, including Constipation, Arrhythmia, Cardiovascular Conditions and Disorders, Neutropenia, and Renal Dysfunction.
Arrhythmia
Moderate:granisetron
Granisetron has a moderate potential interaction with Arrhythmia.
The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.
Cardiovascular Conditions and Disorders
Moderate:granisetron
Granisetron has a moderate potential interaction with Cardiovascular Conditions and Disorders.
The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.
Constipation
Moderate:granisetron
Granisetron has a moderate potential interaction with Constipation.
Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.
Electrolyte Abnormalities
Moderate:granisetron
Granisetron has a moderate potential interaction with Electrolyte Abnormalities.
The IV and oral formulations of granisetron should be used with caution in patients with preexisting arrhythmias or cardiac conduction disorders because QT prolongation has been reported. Patients with cardiac disease, electrolyte abnormalities, cardiotoxic chemotherapy, or concomitant QT-prolonging drugs may be particularly at risk for clinical consequences.
Gastrointestinal Obstruction
Moderate:granisetron
Granisetron has a moderate potential interaction with Gastrointestinal Obstruction.
Granisetron may mask a progressive ileus and/or gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction or following recent abdominal surgery. In patients with preexisting constipation receiving subcutaneous granisetron, consider optimizing bowel regimens.
Neutropenia
Moderate:granisetron
Granisetron has a moderate potential interaction with Neutropenia.
Serious or severe injection site reactions have been reported with the subcutaneous formulation of granisetron. Patients who are neutropenic may be at greater risk; monitor for injection site reactions during treatment and consider discontinuing therapy for severe or persistent reactions.
Renal Dysfunction
Moderate:granisetron
Granisetron has a moderate potential interaction with Renal Dysfunction.
The subcutaneous formulation of granisetron should be avoided in patients with severe renal dysfunction. In patients with moderate renal dysfunction, subcutaneous granisetron should not be administered more frequently than once every 14 days because the clinical significance of potential prolonged elimination of the polymer vehicle is unknown.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.